Company
Headquarters: Taipei, Taiwan
TW$8.06 Billion
TWD as of July 1, 2025
US$275.3 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Orient Pharma Co., Ltd. researches, develops, manufactures, and sells drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson's and Alzheimer's diseases. It is also developing drug delivery technologies, such as multi-stages controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and micro granules. The company was founded in 2008 and is based in Taipei, Taiwan. Orient Pharma Co., Ltd. is a subsidiary of Orient Europharma Co., Ltd.
Orient Pharma Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 4166 wb_incandescent